A. Fleming
7 Papers
1 Citations
A. Fleming is an academic researcher. The author has contributed to research in topics: Insulin & Internal medicine. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders
B. Literáti-Nagy,É. Péterfai,E. Kulcsár,Zs. Literáti-Nagy,B. Buday,Kálmán Tory,József Mandl,Balazs Sumegi,A. Fleming,J. Roth,Laszlo Koranyi +10 more
TL;DR: It is suggested that BGP-15 can be a successful insulin sensitizer agent to prevent side effects of olanzapine treatment and be safe and well tolerated during the whole study period.
33
PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo.
Edwige Schreyer,Cathy Obringer,Nadia Messaddeq,B. Kieffer,Paul Zimmet,A. Fleming,Tarekegn Geberhiwot,Vincent Marion +7 more
TL;DR: PATAS represents a novel first-in-class peptide that targets the adipocyte to ameliorate insulin resistance and its associated comorbidities and reduced whole-body insulin resistance, and improved glucose intolerance, fasting glucose, liver steatosis, and fibrosis in rodents.
6
Diabetes Technology Meeting 2022
Jingtong Huang,Andrea M. Yeung,Ashley Y. DuBord,Howard Wolpert,Peter G. Jacobs,Wei-An Andy Lee,Andjela Drincic,Elias K. Spanakis,Jennifer L. Sherr,Priya Prahalad,A. Fleming,Victoria C. Hsiao,Tejaswi Kompala,Rayhan A. Lal,Maya Fayfman,Barry H. Ginsberg,Rodolfo J. Galindo,Andreas Stuhr,J. Geoffrey Chase,Bijan Najafi,Umesh Masharani,Jane Jeffrie Seley,David C. Klonoff +22 more
TL;DR: A live demonstration of a device that can allow for the recycling of used insulin pens was also presented at the Diabetes Technology Meeting from November 3 to November 5, 2022 as discussed by the authors , where the participants discussed virtual diabetes care, metrics for managing diabetes and predicting outcomes, integration of continuous glucose monitor data into the electronic health record, regulation of diabetes technology, digital health to nudge behavior, estimating carbohydrates, and fully automated insulin delivery systems.
Improvement of Insulin Sensitivity by a Novel Drug, BGP-15, in Insulin-resistant Patients: A Proof of Concept Randomized Double-blind Clinical Trial
B. Literáti-Nagy,E. Kulcsár,Zs. Literáti-Nagy,B. Buday,É. Péterfai,T. Horváth,Kálmán Tory,A. Kolonics,A. Fleming,József Mandl,Laszlo Koranyi +10 more
TL;DR: BGP-15 at 200 or 400 mg significantly improved insulin sensitivity in insulin-resistant, nondiabetic patients during treatment compared to placebo and was safe and well-tolerated in this first clinical study demonstrating the insulin-sensitizing effect of a molecule.
Workshop A: Measurement of Glucose, Insulin, and Ketones—Panel 1: Measurement of Glucose Moderators
Jingtong Huang,Andrea M. Yeung,Ashley Y. DuBord,Howard Wolpert,Peter G. Jacobs,Wei-An Andy Lee,Andjela Drincic,Elias K. Spanakis,Jennifer L. Sherr,Priya Prahalad,A. Fleming,Victoria C. Hsiao,Tejaswi Kompala,Rayhan A. Lal,Maya Fayfman,Barry H. Ginsberg,Rodolfo J. Galindo,Andreas Stuhr,J. Geoffrey Chase,Bijan Najafi,Umesh Masharani,Jane Jeffrie Seley,David C. Klonoff,Edin,F. Aimbe +24 more
TL;DR: A live demonstration of a device that can allow for the recycling of used insulin pens was also presented at the Diabetes Technology Meeting from November 3 to November 5, 2022 as mentioned in this paper , where the participants discussed virtual diabetes care, metrics for managing diabetes and predicting outcomes, integration of continuous glucose monitor data into the electronic health record, regulation of diabetes technology, digital health to nudge behavior, estimating carbohydrates, and fully automated insulin delivery systems.